Back to top
more

Pulmonx (LUNG)

(Real Time Quote from BATS)

$7.62 USD

7.62
85,818

+0.12 (1.60%)

Updated Apr 24, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 5% and 9.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pulmonx Corporation (LUNG) Q3 Earnings Expected to Decline

by Zacks Equity Research

Pulmonx Corporation (LUNG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medical Info System Stocks to Gain on Rising Demand for Digital Health

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.

Down 27.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Pulmonx Corporation (LUNG)

by Zacks Equity Research

Pulmonx Corporation (LUNG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 78.6% in Pulmonx Corporation (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.44% and 1.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Pulmonx Corporation (LUNG) Climb 117% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 117.5% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Privia Health (PRVA) Moves 7.4% Higher: Will This Strength Last?

by Zacks Equity Research

Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Pulmonx Corporation (LUNG) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 24.32% and -0.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.

Boston Scientific (BSX) Product Launches to Drive Q3 Earnings

by Zacks Equity Research

Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.

Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.